PreveCeutical Medical Inc.

PreveCeutical Medical Inc. is a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature identical products.

Recent News

  • Retraction to News Release dated April 4, 2019

    Vancouver, British Columbia--(Newsfile Corp. - April 4, 2019) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), announces that, at the request of the Investment Industry Regulatory Organization of Canada, it hereby retracts certain statements regarding estimated annual production, valuation and harvest quantities from the ...

    2019-04-04 5:09 PM ET
  • Asterion Welcomes Australian Government Awarding of Major Project Status for its Toowoomba Medicinal Cannabis Project

    Vancouver, British Columbia--(Newsfile Corp. - April 4, 2019) - Asterion Cannabis Inc. (P.ASTR) ("Asterion") and PreveCeutical Medical Inc. ("PreveCeutical") (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H), announce today that Asterion's wholly-owned Australian subsidiary, Asterion Australia Pty Ltd, has been awarded Major Project Status for Asterion's Toowoomba Medicinal Cannabis Project (the "Toowoomba ...

    2019-04-04 2:40 PM ET
  • PreveCeutical Announces Default Judgment Against Essos Corporate Services Inc. and Detona Capital Corp.

    Vancouver, British Columbia--(Newsfile Corp. - March 25, 2019) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), announces that it has obtained a default judgement against each of Essos Corporate Services Inc. ("Essos") and Detona Capital Corp. ("Detona") in connection with a Supreme Court of ...

    2019-03-25 8:00 AM ET
  • PreveCeutical Announces Preliminary Screening Results of Peptides Derived From Blue Scorpion Venom in a Cell-Based Brain Cancer Model

    Vancouver, British Columbia--(Newsfile Corp. - March 11, 2019) -  PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to announce positive results from the preliminary screening of key peptides from its scorpion venom-derived peptide research and development program (the "Peptide Program"), that is expected to enable ...

    2019-03-11 9:00 AM ET
  • PreveCeutical Announces Appointment of Dr. Makarand Jawadekar as President

    Vancouver, British Columbia--(Newsfile Corp. - February 13, 2019) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical") is pleased to announce the appointment of Dr. Makarand (Mak) Jawadekar as the President of the Company, effective immediately. Dr. Jawadekar will also continue as the Chief ...

    2019-02-13 9:30 AM ET
  • PreveCeutical Announces Closing of Non-Brokered Private Placement

    Vancouver, British Columbia--(Newsfile Corp. - February 12, 2019) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical") announces the closing of a non-brokered private placement financing (the "Financing"). A total of 6,100,000 units (the "Units") were issued under the Financing at a price of $0.05 ...

    2019-02-12 9:30 AM ET
  • PreveCeutical to Explore Partnerships with Pharmaceutical and Biotechnology Companies for the Co-Development of its Sol-Gel System

    Vancouver, British Columbia--(Newsfile Corp. - January 29, 2019) - PreveCeutical Medical Inc. (the "Company" or "PreveCeutical") (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H), announces that it plans to commence exploratory discussions with pharmaceutical and biotechnology companies developing therapies for neurological disorders, that are seeking a targeted nose-to-brain drug delivery system ...

    2019-01-29 9:00 AM ET
  • PreveCeutical Provides Update on the Dual Gene Therapy Program

    Vancouver, British Columbia--(Newsfile Corp. - January 14, 2019) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical") is pleased to provide an update on its dual gene therapy program, an important and fundamental aspect of which involves the design, synthesis and screen

    2019-01-14 9:30 AM ET